Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), recently sold shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. On March 5, Moshkevich sold a total of 6,000 shares, with transaction prices ranging from $142.08 to $144.97 per share. The total value of these transactions amounted to approximately $859,734. The sale comes as Natera’s stock has shown significant volatility, with a -9.6% return over the past week despite an impressive 58% gain over the last year.
Following these sales, Moshkevich holds 143,768 shares of Natera. The sales were conducted as part of a pre-arranged Rule 10b5-1 trading plan, which was established on November 26, 2024. According to InvestingPro analysis, Natera maintains strong financial health with a current ratio of 4.0, indicating solid liquidity. The company’s stock is currently trading above its Fair Value, with 13 additional exclusive ProTips available for subscribers seeking deeper insights into Natera’s financial outlook.
In other recent news, Natera has reported its fourth-quarter 2024 earnings, showcasing a strong financial performance that exceeded Wall Street expectations. The company reported a revenue of $476 million, surpassing the forecasted $409.89 million, and achieving a 53% year-over-year growth. Earnings per share were reported at -$0.41, better than the anticipated -$0.49, alongside improved gross margins of 63%. Following these results, Canaccord Genuity raised its price target for Natera to $195, citing optimism about the company’s projected revenue growth for 2025, which is expected to be in the mid-20% range. TD Cowen also maintained a Buy rating with a $195 target, highlighting Natera’s promising 2025 guidance that exceeded consensus estimates. The company’s strategic focus on operational expenditures and cash flow improvements further supports a positive outlook. Additionally, the firm has seen significant growth in test volumes and consistent positive operating cash flows, indicating a stable financial trajectory. These developments reflect a robust year for Natera, with strong future prospects as noted by analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.